FOI 24/25- 0013
DOCUMENT 16
Research – Alternative Funding Sources for Rituximab
Please investigate alternative options a participant could possibly access
Brief
funding to assist them to purchase medications (in this case Rituximab) not
approved by the PBS.
Date
19/03/2021
Requester(s)
Lee s22(1)(a)(ii) - irre – ( Director – Compensation Recoveries Branch)
Researcher
Jane s22(1)(a)(ii) - irrelev (R esearch Team Leader - TAB)
Cleared
N/A
Please note:
The research and literature reviews col ated by our TAB Research Team are not to be shared external to the Branch. These
are for internal TAB use only and are intended to assist our advisors with their reasonable and necessary decision-making.
Delegates have access to a wide variety of comprehensive guidance material. If Delegates require further information on
access or planning matters they are to call the TAPS line for advice.
The Research Team are unable to ensure that the information listed below provides an accurate & up-to-date snapshot of
these matters.
Contents
2 Rituximab ........................................................................................................................................ 1
3 Pharmaceutical Company Compassionate Programs ..................................................................... 2
3.1
Roche ...................................................................................................................................... 2
3.2
Cellitron ................................................................................................................................... 3
3.3
Sandoz ..................................................................................................................................... 3
4 Lions Club ........................................................................................................................................ 3
5 Rotary Australia............................................................................................................................... 4
6 References ...................................................................................................................................... 5
Rituximab
Page 148 of 425
FOI 24/25- 0013
Rituximab is a human-murine chimeric anti-CD20-antibody, originally approved for B-cell lymphoma
[1]. Upon intravenous administration, it causes rapid and complete depletion of B cel s through
complement mediated mechanisms in the blood and, to a lesser degree, also in the cerebrospinal
fluid [1].
The drug is not approved for use in Devic’s disease, however, has been studied as a disease
modifying treatment in multiple sclerosis (MS) with good outcomes [1]. Roche investigated the use
of Rituximab in MS which yielded promising signs of efficacy, but development in this indication was
discontinued for undisclosed reasons [2]. Regulatory approval for the treatment of MS currently
does not exist.
In Australia, Rituximab is marketed as:
• Mabthera –Roche
• Riximyo - Sandoz
• Truxima – Cellitron Healthcare Australia
All are approved for use in Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL),
Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis (GPA), Microscopic Polyangiitis (MPA).
Pharmaceutical Company Compassionate Programs
Drugs that are unapproved for the indication for which they are being requested on compassionate
grounds are more challenging to acquire and contribute a significant proportion of likely requests
[3].
3.1
Roche
Roche has a positon statement relating to access to medicines outside of public funding. In summary
[4]:
• Roche’s aim is for every person who needs our medicines to be able to benefit from them
• The Federal and State Governments have primary responsibility for Australia’s universal
healthcare system, which provides subsidised access to many medicines via the
Pharmaceutical Benefits Scheme (PBS) and public hospitals.
• Roche acknowledges that the absence of public funding for a prescribed medicine may
represent a significant financial burden and difficult choice for patients.
Page 149 of 425
FOI 24/25- 0013
• In situations where there is no public funding, Roche may be able to assist patients with
alternative mechanisms of access to medicines, such as providing subsidies.
o Al requests for access in these circumstances must come to Roche via a patient’s
treating healthcare professional.
In relation to investigational medicinal products, new medicines may be made available to individual
patients in special circumstances [5]. For example:
• Compassionate Use (CU): is a mechanism to provide a new medicine to an individual patient
or set of individual patients who have a serious or life threatening disease or condition for
which no satisfactory alternative therapy exists or who cannot enter a clinical trial.
3.2
Cellitron
Unable to locate a compassionate use program for this company.
3.3
Sandoz
Novartis (Sandoz is a division of Novartis) delivers what is called a ‘managed access program’. This
program allows patients with serious or life threatening diseases or conditions access to certain
investigational or unapproved treatments [6].
The Novartis “Managed Access” terminology covers all locally defined pre-approval access
mechanisms and programs such as “Compassionate Use”, “Expanded Access”, “Named Patient
Supply”, “Special Access Schemes/Programs” etc.
The treating physician can request an investigational or pre-approval product prior to regulatory
approval, provided it is allowed by the applicable local laws.
Lions Club
The Lions Club International Foundation (LCIF) supports large-scale projects that address
unmet humanitarian needs for entire communities. These projects are led by local Lions who
identify the need, develop the plan of action and carry out the project. LCIF does not have a
grant program that supports individual assistance. These requests are more appropriately
Page 150 of 425
FOI 24/25- 0013
directed to the local Lions who often have programs in place to support these types of
requests within their communities.
The participant’s local club is Rochedale Springwood – District 201Q1
Rotary Australia
In January 2017, Rotary Australia announced its Compassionate Grants program to help Australians
in need.
Grants are assessed by the Rotary Australia Benevolent Society (RABS) and funds distributed
to
disadvantaged Australians identified by local Rotary Clubs or Rotary Districts as being in need
within their local or wider community.
Projects granted funding must meet RABS criteria for registration. They must provide direct relief to
people in need. If the intended recipients are disadvantaged, the relief should target that
disadvantage.
The concept of disadvantage is unlimited and could have arisen from sickness, suffering, distress,
misfortune, disability, destitution, helplessness or poverty, any aspect of the negative side of the
human condition. The criteria are not prescriptive but are to be used as a guide to determine the
disadvantage.
Sample projects where person or group was potentially disadvantaged under the above criteria:
Provision of a modified family motor vehicle for a 6 year old with cerebral palsy
Modifications to a home to assist access and functionality for a quadriplegic
Financial assistance for a seriously injured sportsman’s family
Ongoing support for non PBS medicines for a sufferer of Lymes disease
Provision of a specialised bed for a person with Parkinson’s Disease
Supply insulin pumps to three children with juvenile diabetes
Provision of improved prosthetics for an amputee
Assistance to a family who lost everything in a fire
Provision of financial assistance to a young family whose mother drowned
Page 151 of 425
FOI 24/25- 0013
References
1.
Ineichen BV, Moridi T, Granberg T, Piehl F. Rituximab treatment for multiple sclerosis.
Multiple Sclerosis Journal [Internet]. 2019 2020/02/01; 26(2):[137-52 pp.]. Available from:
https://doi.org/10.1177/1352458519858604.
2.
Mullard A. Roche hits multiple sclerosis landmarks. Nature Reviews Drug Discovery
[Internet]. 2015 2015/11/01; 14(11):[739- pp.]. Available from: https://doi.org/10.1038/nrd4780.
3.
Medicines Australia. Navigating (Compassionate) Access to Medicines For Trials 2020.
Available from: https://www.medicinesaustralia.com.au/wp-content/uploads/2020/11/Whitepaper-
Navigating-compassionate-access-to-medicines-for-trials-for-reviewspplus-august2020-1.pdf.
4.
Roche. Access to medicines outside of public funding Roche Australia (Pharmaceuticals)
Policy Position 2016 [Available from: https://www.roche-
australia.com/content/dam/rochexx/roche-au/roche australia/en en/media/publications/2016-
10%20Roche%20Position%20-
%20Access%20to%20Medicines%20Outside%20of%20Public%20Funding.pdf.
5.
Roche. RochePosition on Pre-Approval Access to Investigational Medicinal Products 2020
[Available from: https://www.roche.com/dam/jcr:035f3847-505e-484c-b5f6-
f666790791de/en/24 Position Pre Approval Access Investigational Medicinal Products reviewed
April 2020.pdf.
6.
Novartis. Novartis Position on Pre-Approval Access to Novartis Products through Novartis
Managed Access Programs (MAPs) 2019 [Available from:
https://www.novartis.com/sites/www.novartis.com/files/novartis-position-pre-approval-access.pdf.
Page 152 of 425
